http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

proactive investor -

Shares in Oxford Pharmascience (LON:OXP) advanced almost 20% this week as it revealed data on its safer version of a top selling painkiller.

OXP’s study indicated its OXPzero Ibuprofen could reduce stomach irritation side-effects. And although the research was only conducted on mice, the breakthrough could be significant.

Target price raised to 9.2p:

Oxford Pharmascience price target raised 33% by N+1 Singer
By Ian Lyall May 15 2013, 1:56pm

According to the NHS, ibuprofen can cause a number of side effects, including nausea, vomiting, diarrhoea, indigestion and abdominal pain.

City broker N+1 Singer has raised its valuation of Oxford Pharmascience (LON:OXP) by 33% to reflect the potential of its adaptation of a top selling painkiller.

Its target price rises to 9.2 pence a share, representing a significant premium to the current share price of 3.92 pence.

The upgrade follows pre-clinical data last week that indicated OXPzero ibuprofen could reduce stomach irritation side-effects.

While the study was only conducted on mice, the breakthrough could be significant.

The genetic and biological characteristics of mice are close to those of humans, which is one of the reasons they are so widely used in medical research.

The pharmacological trial showed that Oxford’s OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

Ibuprofen, along with the likes of aspirin and paracetamol, is one of the main “go-to” pain killers available over the counter today.

It has long been proved to be effective in easing pain and swelling, and is a member of a group of medicines called non-steroidal anti-inflammatory drugs, or NSAIDs for short.

According to the NHS, ibuprofen can cause a number of side effects, including nausea, vomiting, diarrhoea, indigestion and abdominal pain.

“The successful data from the proof of concept pre-clinical trial is a very significant and important step for the group,” said N+1 analyst Sheena Berry.

“The initiation of the NSAIDs programme is very interesting and one that could be very rewarding given the size of the US$12bn NSAIDs market.

“The change in focus to the higher value pharmaceutical market in 2011 is proving to have been a pivotal decision and one, in our view, that has the potential to reap significant benefits.”

Since hitting a low in September last year the stock advanced more than 330%, but is still valued at less than £30mln.

However, analyst Berry remains optimistic on the outlook for the stock.

“We continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market,” she added.

Good news d ,9.2p

The drinks are on you then when that happens dc - I would like a nicely chilled glass of Sancerre, thank you !:-)

Lol, have what ever you would like d.

Hitting an all time high right now.

Oxford Pharmascience Group PLC (OXP:LSE) set a new 52-week high during today's trading session when it reached 4.30. Over this period, the share price is up 214.81%.

10million 'O' trade just gone through at 4.125p

Some big trades going through after the close tonight.

Bodes well d4. :-))


Oxford Pharma brings new life to tried and tested drugs
By Proactive Investors May 22 2013, 8:45am
Marcelo Bravo, Chief Technology Officer at Oxford Pharmascience (LON:OXP), explains to Proactiveinvestors how the company re-engineers existing drugs to improve the way they work and overcome side effects. Marcelo discusses the recent successful study for ibuprofen and the launch of the safer NSAID programme, the news of which drove shares to two year highs.


http://www.proactiveinvestors.co.uk/companies/stocktube/2001/oxford-pharma-brings-new-life-to-tried-and-tested-drugs-2001.html

2 RNS just out - Invesco picked up another 20 million shares earlier this week.

Holding(s) in Company

RNS

UBS Investment Bank



http://www.moneyam.com/action/news/showArticle?id=4603160

10million buy declared at 18.26.

2 RNS just out. UBS increasing their holding.

Ache Line Extension

RNS


RNS Number : 1350G

Oxford Pharmascience Group PLC

04 June 2013




Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience announces line extension for Brazil



Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces that it has agreed a line extension in Brazil with its Brazilian partner Aché Pharmaceuticos (Aché) for a new version of its calcium and vitamin D chew marketed under the brand name Inellare.

Sales to Aché of this new format are expected to begin in Q3 2013.



Nigel Theobald, Chief Executive Officer of Oxford Pharmascience commented,

"Our chew business in Brazil continues to grow strongly and the addition of a new version of our calcium product in the Brazilian market shows both the commitment of our partner and the ongoing potential for the range."

Oxford Pharmascience (LON:OXP), which specialises in reformulating tried and tested medicines, has agreed a line extension in Brazil with its Brazilian partner Aché Pharmaceuticos.

The deal is for a new version of Oxford’s calcium and vitamin D chew marketed under the brand name Inellare.

Broker N+1 Singer speculated that the new line being introduced is a sugar-free version of the calcium and vitamin D chew.

As it had already forecast this development, it is making no changes to its estimates, adding that it expects both the sugar and sugar-free versions of the chew to achieve modest growth, with minimal cannibalisation of market share.

“This morning’s news is evidence of Oxford Pharmascience continuing to deliver, with on-going progress being made in all three of its technology platforms,” it said.

“We maintain upbeat about the group and believe it is capable of becoming a major player in the re-formulation market. We recently upgraded our intrinsic value per share to 9.2p on the back of the successful proof of concept data with OXP zero and await further updates on the group’s development progression.”

Interesting post today on the other bulletin board by a shareholder who attended the AGM.

RNS Number : 5335J
Oxford Pharmascience Group PLC
17 July 2013



Oxford Pharmascience Group plc



("Oxford Pharmascience" or "the Company")



Oxford Pharmascience appoints Head of Clinical Development



Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces it has appointed Sheryl Caswell as Clinical Development Manager. Sheryl will be responsible for leading and executing the company's clinical development strategy focused on the company's two main medicines reformulation programmes in NSAIDs and Statins with reduced side effects. Sheryl will be a member of Oxford Pharmascience's management team reporting to Marcelo Bravo, chief technology officer.

Sheryl has more than 15 years of experience developing and executing global clinical programs for novel and first-in-class products from Phase I through Phase IV, with particular experience in early phase clinical development. Most recently as Clinical Programme Lead at Biogen Idec Ltd, she led the clinical programmes of two of the company's product candidates in neurology. Prior to that she served as Programme Director and Director of Clinical Research for Plethora Solutions where she led the clinical function as well as had overall clinical development responsibility for early phase products.

"Sheryl Caswell is joining Oxford Pharmascience at an exciting time in the company's evolution. We are progressing to human proof of concept trials in both our NSAIDs and Statin programmes and Sheryl will play a key role in making this happen," said Marcelo Bravo, Chief Technology Officer. "We look forward to leveraging Sheryl's extensive global clinical development experience as we advance our two main programmes in reformulation of NSAIDs and Statins with reduced side effects".

The road to market for most drugs is a long and arduous one, but the signs at Oxford Pharmascience (LON:OXP) are that everything is proceeding to plan, according to N+1 Singer.

The pharmaceutical company announced on Tuesday that industry veteran Sheryl Caswell has joined the company as clinical development manager, to oversee the company's clinical development strategy.

House broker N+1 Singer said: “The new appointment is an indication of the next phase of the group’s existing development plan, with progress towards human proof of concept trials in both the NSAIDs and statin programmes continuing as anticipated.”

The broker reiterated its 9.2p intrinsic value per share number for Oxford, saying it remains upbeat about the company, which it believes “is capable of becoming a major player in the reformulation market.”

Option with UCL to Explore Further Compounds

RNS


RNS Number : 0548K

Oxford Pharmascience Group PLC

25 July 2013






Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience signs option with UCL to explore further compounds.



Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that it has signed an option agreement with UCL ("University College London" to investigate 53 further compounds that it could potentially commercialise using UCL's Phloral™ technology.



Following closely working with UCL on the Company's program for Atorvastatin and Simvastatin, it has identified a further 53 compounds which might benefit from reformulation using Phloral™ to reduce their associated side effects.



The Company has agreed an option period until March 2014 to investigate the potential for these compounds with a further option period for another year to explore more thoroughly those compounds that it will identify to have the greatest commercial and clinical potential.





Nigel Theobald Chief Executive of Oxford Pharmascience commented



"Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programs for NSAIDs (non steroidal anti inflammatory drugs) and Statins.



There are many other drugs widely used where side effects reduce the tolerance or compliance in patients. This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programs.



We are committed to building a strong portfolio of reformulated drugs to deliver the high returns of new drug development but without the high risks."